ReviewChemical science2026
Engineering peroxygenases for pharmaceutical applications: recent advances and future perspectives.
Review in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective oxidation is a cornerstone process in pharmaceutical biosynthesis, as it enables the conversion of inert C-H bonds into valuable functional groups such as alcohols, ketones, epoxides, and carboxylic acids, which serve as important intermediates in drug synthesis. Peroxygenases, including unspecific peroxygenases and P450 peroxygenases, have emerged as powerful biocatalysts for enzymatic oxidation, with growing applications in metabolite synthesis, late-stage C-H functionalization, and the preparation of enantioenriched intermediates for pharmaceutical development. In this review, we present the latest advances in peroxygenases engineering for pharmaceutical applications. We summarize pharmaceutical drug candidates that can serve as substrates for peroxygenases, discuss the enzymatic oxidation pathways mediated by peroxygenases for these substrates, and outline protein engineering strategies employed to improve the catalytic performance and properties of peroxygenases in pharmaceutical biosynthesis. We also discuss the potential of emerging artificial intelligence (AI) strategies for multi-dimensional peroxygenase engineering including catalytic activity, thermostability, hydrogen peroxide tolerance, heterologous expression, substrate scope, regioselectivity, and enantioselectivity. Overall, continued progress in peroxygenase engineering will drive the transformation of these biocatalysts for versatile industrial applications, thereby enabling sustainable drug synthesis, efficient metabolite production, and innovative therapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.